Linked Life Data

11926750

Source:http://linkedlifedata.com/resource/pubmed/id/11926750

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2002-4-2
pubmed:abstractText
Cardiac allograft vasculopathy is the most common cause of death and retransplantation following heart transplantation, and about 10% of patients per year have evidence of accelerated vascular disease; 50% at 5 years. Cytomegalovirus (CMV) infection has been associated with accelerated cardiac vasculopathy and decreased 5-year survival. Prophylactic therapy using ganciclovir has reduced the incidence of CMV disease, but not in the group at highest risk, namely the seronegative recipient of an allograft from a seropositive donor (D+/R-). Combination prophylaxis consisting of CMV hyperimmune globulin (CMV-IGIV) plus ganciclovir is associated with decreased intimal thickening, reduced coronary artery disease and obliterative bronchiolitis, and improved survival.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1398-2273
pubmed:author
pubmed:issnType
Print
pubmed:volume
3 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
44-8
pubmed:dateRevised
2009-10-8
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
Role of cytomegalovirus in cardiac allograft vasculopathy.
pubmed:affiliation
University of Alabama at Birmingham, USA. dweill@uab.edu
pubmed:publicationType
Journal Article, Review